Latest Eribulin Stories
FOR U.S. MEDIA ONLY WOODCLIFF LAKE, N.J., Dec.
The cancer drug eribulin, originally developed from sea sponges, could give women with advanced triple negative breast cancer an average of five extra months of life
Tokyo, Sept 17, 2014 - (JCN Newswire) - Eisai Co., Ltd.
Tokyo, July 3, 2014 - (JCN Newswire) - Eisai Co., Ltd.
Indication of Anticancer Agent Halaven for Use in Earlier-Line Treatment of Advanced Breast Cancer Tokyo, May 27, 2014 - (JCN Newswire)
Data underscore breadth of oncology portfolio WOODCLIFF LAKE, N.J., May 14, 2014 /PRNewswire/ -- Eisai Inc.
Patient Recruitment Now Underway at Treatment Centers Across the United States WOODCLIFF LAKE, N.J., Feb. 27, 2014 /PRNewswire/ -- Eisai Inc.
Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits.
- A poem in which the author retracts something said in an earlier poem.